サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1684478

注意欠陥多動性障害 (ADHD) 治療薬市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)

Attention Deficit Hyperactivity Disorder Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 250 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
注意欠陥多動性障害 (ADHD) 治療薬市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)
出版日: 2025年03月19日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の注意欠陥多動性障害（ADHD）治療薬市場の詳細な分析を発表し、市場促進要因・動向・機会・課題など主要な市場力学の詳細な評価を提供しています。当レポートでは、2025年から2032年までのADHD治療薬市場の予測成長軌道を概説する独占データと統計的洞察をお届けします。

主要な洞察

  • 注意欠陥多動性障害 (ADHD) 治療薬の市場規模 (2025年)：153億米ドル
  • 市場規模の予測 (金額ベース、2032年)：4,310万米ドル
  • 世界市場の成長率 (CAGR、2025～2032年)：15.9%

注意欠陥多動性障害 (ADHD) 治療薬市場：分析範囲

注意欠陥多動性障害（ADHD）は、一般的に小児で診断され、しばしば成人期まで続く神経発達障害です。ADHD治療薬市場は、不注意、衝動性、多動性などの症状を管理することを目的とした薬理学的治療と非薬理学的治療で構成されます。同市場は、小児、青年、成人など多様な患者集団を対象としており、治療選択肢は刺激薬、非刺激薬から行動療法まで多岐にわたる。ADHDに対する認識の高まりは、治療選択肢の進歩や早期診断の取り組みと相まって、市場拡大の原動力となっています。さらに、ADHDの有病率の増加とADHD管理のための遠隔医療サービスの採用の増加は、市場成長に影響を与える主な要因です。

市場成長の促進要因：

世界のADHD治療薬市場は主に、さまざまな年齢層でADHDの有病率が上昇していることが原動力となっています。特に先進地域における認知度の向上と診断能力の向上が、治療率の向上に寄与しています。さらに、徐放性薬剤や新規の非刺激性治療薬を含む薬剤製剤の進歩が、治療効果と患者のコンプライアンスを高めています。ADHDの診察にデジタルヘルスプラットフォームや遠隔医療が採用されるようになったことで、治療へのアクセスがさらに拡大しています。さらに、個別化医療やADHDに影響を与える遺伝的要因の調査は、将来の治療アプローチに革命をもたらすと期待されています。

市場の抑制要因：

ADHD治療薬市場は、大きな成長の可能性があるにもかかわらず、不眠、食欲低下、心血管リスクなど、刺激薬の副作用に関する懸念などの課題に直面しています。さらに、新薬承認のための規制上のハードルや厳しい処方ガイドラインは、市場の拡大を制限する可能性があります。ADHD治療薬、特に長期治療薬の価格が高いことは、特に中低所得国において、購入しやすい価格であるかどうかという課題となっています。さらに、特定の地域では社会的偏見や過小診断が治療導入の障壁となっています。

市場機会：

ADHD治療薬市場は、薬剤製剤の技術革新や代替治療アプローチによって、大きなビジネスチャンスをもたらしています。認知行動療法（CBT）、ニューロフィードバック、食事介入を含む非刺激剤治療は、補完的治療または単独治療として支持を集めています。遺伝的・神経生物学的要因に関する調査が拡大し、個々の患者のニーズに合わせた精密医療への道が開かれつつあります。さらに、ADHDの診断や治療モニタリングにおける人工知能（AI）の役割の増大は、医療提供者や製薬会社に新たな成長の道を提供しています。また、市場プレイヤーは、デジタルヘルスプラットフォームや遠隔医療ソリューションを通じて、薬剤開発を強化し、患者アクセスを改善するための戦略的提携を模索しています。

当レポートで回答する主な質問

  • ADHD治療薬市場の世界の成長を促進する主な要因は何か？
  • 技術の進歩はADHD治療の将来をどのように形成しているか？
  • 市場拡大に影響を与える主な課題と抑制要因は何か？
  • ADHD治療薬市場の主要企業はどこか？競争優位に立つためにどのような戦略を実施しているのか？
  • ADHD治療薬市場の新たな動向と投資機会は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 市場の革新/開発動向

第4章 重要成功要因

  • 薬物の採用/使用分析
  • 疾病疫学
  • 払い戻しシナリオ
  • パイプライン分析
  • バリューチェーン分析
  • 主要な規制シナリオ
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因：関連性と影響
  • 市場力学

第6章 COVID-19危機の分析

  • COVID-19と影響分析
    • 薬剤別
    • 年齢別
    • 流通チャネル別
    • 国別
  • 2022年の市場シナリオ

第7章 世界のADHD治療薬市場の需要の分析（金額 (10億米ドル)・数量ベース）

  • 過去の市場規模の分析 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測 (10億米ドル、2025～2032年)
    • 前年比成長動向の分析
    • 絶対的収益機会の分析

第8章 世界のADHD治療薬市場の展望：薬剤別（2019年～2032年）

  • イントロダクション/主な調査結果
  • 過去の市場規模の分析：薬剤別 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測：薬剤別 (10億米ドル、2025～2032年)
    • 覚醒剤
      • アンフェタミン
      • メチルフェニデート
      • デキストロアンフェタミン
      • デキスメチルフェニデート
      • リスデキサンフェタミンジメシル酸塩
    • 非刺激性物質
      • アトモキセチン
      • ブプロピオン
      • グアンファシン
      • クロニジン
  • 市場魅力分析：薬剤別

第9章 世界のADHD治療薬市場の展望：年齢層別（2019年～2032年）

  • イントロダクション/主な調査結果
  • 過去の市場規模の分析：年齢層別 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測：年齢層別 (10億米ドル、2025～2032年)
    • 小児・青年
    • 成人
  • 市場魅力分析：年齢層別

第10章 世界のADHD治療薬市場の展望：流通チャネル別（2019年～2032年）

  • イントロダクション/主な調査結果
  • 過去の市場規模の分析：流通チャネル別 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測：流通チャネル別 (10億米ドル、2025～2032年)
    • 専門クリニック
    • 病院薬局
    • 小売薬局
    • eコマース
  • 市場魅力分析：流通チャネル別

第11章 世界のADHD治療薬市場の展望：地域別（2019年～2032年）

  • イントロダクション
  • 過去の市場規模の分析：地域別 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測：地域別 (10億米ドル、2025～2032年)
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場魅力分析：地域別

第12章 北米のADHD治療薬市場の展望（2019～2032年）

第13章 ラテンアメリカのADHD治療薬市場の展望（2019～2032年）

第14章 欧州のADHD治療薬市場の展望（2019～2032年）

第15章 東アジアのADHD治療薬市場の展望（2019～2032年）

第16章 南アジアのADHD治療薬市場の展望（2019～2032年）

第17章 オセアニアのADHD治療薬市場の展望（2019～2032年）

第18章 中東・アフリカ（MEA）のADHD治療薬市場の展望（2019～2032年）

第19章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Pfizer Inc.
    • Eli Lilly and Company
    • Novartis AG
    • GlaxoSmithKline PLC
    • Mallinckrodt Pharmaceuticals
    • Hisamitsu Pharmaceutical Co., Inc.
    • Johnson &Johnson
    • UCB SA
    • Purdue Pharma LP

第21章 使用される仮定と頭字語

第22章 調査手法

目次
Product Code: PMRREP4222

Persistence Market Research has recently published an in-depth analysis of the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market, providing a detailed evaluation of key market dynamics, including drivers, trends, opportunities, and challenges. The report delivers exclusive data and statistical insights outlining the projected growth trajectory of the ADHD therapeutics market from 2025 to 2032.

Key Insights:

  • Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2025E):US$ 15.3 Bn
  • Projected Market Value (2032F): US$ 43.1 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 15.9%

ADHD Therapeutics Market - Report Scope

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder commonly diagnosed in children and often persisting into adulthood. The ADHD therapeutics market comprises pharmacological and non-pharmacological treatments aimed at managing symptoms such as inattention, impulsivity, and hyperactivity. The market serves a diverse patient population, including children, adolescents, and adults, with treatment options ranging from stimulant and non-stimulant medications to behavioral therapies. The increasing awareness of ADHD, coupled with advancements in treatment options and early diagnosis initiatives, is driving market expansion. Additionally, the growing prevalence of ADHD and rising adoption of telehealth services for ADHD management are key factors influencing market growth.

Market Growth Drivers

The global ADHD therapeutics market is primarily driven by the rising prevalence of ADHD across different age groups. Increased awareness and better diagnostic capabilities, particularly in developed regions, are contributing to higher treatment rates. Additionally, advancements in drug formulations, including extended-release medications and novel non-stimulant therapies, are enhancing treatment efficacy and patient compliance. The increasing adoption of digital health platforms and telemedicine for ADHD consultations is further expanding access to treatment. Moreover, research into personalized medicine and genetic factors influencing ADHD is expected to revolutionize future therapeutic approaches.

Market Restraints

Despite strong growth potential, the ADHD therapeutics market faces challenges such as concerns regarding the side effects of stimulant medications, which can include insomnia, decreased appetite, and cardiovascular risks. Additionally, regulatory hurdles for new drug approvals and stringent prescription guidelines can limit market expansion. The high cost of ADHD medications, particularly for long-term treatment, poses a challenge for affordability, especially in low- and middle-income countries. Furthermore, social stigma and underdiagnosis in certain regions act as barriers to treatment adoption.

Market Opportunities

The ADHD therapeutics market presents significant opportunities driven by innovation in drug formulations and alternative treatment approaches. Non-stimulant therapies, including cognitive behavioral therapy (CBT), neurofeedback, and dietary interventions, are gaining traction as complementary or standalone treatments. Expanding research into genetic and neurobiological factors is paving the way for precision medicine approaches tailored to individual patient needs. Additionally, the increasing role of artificial intelligence (AI) in ADHD diagnosis and treatment monitoring offers new growth avenues for healthcare providers and pharmaceutical companies. Market players are also exploring strategic collaborations to enhance drug development and improve patient access through digital health platforms and telemedicine solutions.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the ADHD therapeutics market globally?
  • How are technological advancements shaping the future of ADHD treatment?
  • What are the major challenges and restraints impacting market expansion?
  • Who are the key players in the ADHD therapeutics market, and what strategies are they implementing to gain a competitive edge?
  • What are the emerging trends and investment opportunities in the ADHD therapeutics market?

Competitive Intelligence and Business Strategy

Leading companies in the global ADHD therapeutics market, including Johnson & Johnson, Eli Lilly and Company, Novartis AG, and Takeda Pharmaceutical Company, are focusing on innovation, strategic partnerships, and product portfolio expansion. These companies are investing in research and development (R&D) to introduce novel drug formulations with improved efficacy and fewer side effects. Mergers, acquisitions, and collaborations with healthcare providers and telemedicine platforms are further enhancing market penetration. Additionally, pharmaceutical firms are emphasizing patient awareness campaigns and educational programs to promote early diagnosis and treatment adherence.

Key Companies Profiled:

  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • GlaxoSmithKline PLC
  • Mallinckrodt Pharmaceuticals
  • Hisamitsu Pharmaceutical Co., Inc.
  • Johnson & Johnson
  • UCB S.A.
  • Purdue Pharma L.P.

Key Segments Covered in Attention Deficit Hyperactivity Disorder Therapeutics Industry Research

Drug:

  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine

Age Group:

  • Pediatric and Adolescent
  • Adults

Distribution Channel:

  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Market Innovation / Development Trends

4. Key Success Factors

  • 4.1. Drug Adoption/Usage Analysis
  • 4.2. Disease Epidemiology
  • 4.3. Reimbursement Scenario
  • 4.4. Pipeline Analysis
  • 4.5. Value Chain Analysis
  • 4.6. Key Regulatory Scenario
  • 4.7. PESTEL Analysis
  • 4.8. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Neurological Disorder Drugs Market Overview
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Impact of Lifestyle on Disease Progression
    • 5.2.2. Rising Awareness on Neurological and Neuropsychiatric Disorders
    • 5.2.3. Growing Disease Prevalence Globally
    • 5.2.4. Rising R&D Efforts for Novel Drug Development
    • 5.2.5. Availability of Treatment Modalities
    • 5.2.6. Established Genetic Impact on the Etiology of ADHD
    • 5.2.7. Cost of Treatment
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug
    • 6.1.2. By Age Group
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Country
  • 6.2. 2022 Market Scenario

7. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Demand (in Value or Size in US$ Bn) Analysis 2019-2024 and Forecast, 2025-2032

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2024
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2025-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Drug

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Drug, 2019-2024
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2025-2032
    • 8.3.1. Stimulants
      • 8.3.1.1. Amphetamine
      • 8.3.1.2. Methylphenidate
      • 8.3.1.3. Dextroamphetamine
      • 8.3.1.4. Dexmethylphenidate
      • 8.3.1.5. Lisdexamfetamine Dimesylate
    • 8.3.2. Non-stimulants
      • 8.3.2.1. Atomoxetine
      • 8.3.2.2. Bupropion
      • 8.3.2.3. Guanfacine
      • 8.3.2.4. Clonidine
  • 8.4. Market Attractiveness Analysis By Drug

9. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Age Group

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Age Group, 2019-2024
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Age Group, 2025-2032
    • 9.3.1. Pediatric and Adolescent
    • 9.3.2. Adults
  • 9.4. Market Attractiveness Analysis By Age Group

10. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2025-2032
    • 10.3.1. Specialty Clinics
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Retail Pharmacies
    • 10.3.4. E-Commerce
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2024
  • 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Drug
    • 12.3.3. By Age Group
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug
    • 12.4.3. By Age Group
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Drug
        • 12.8.1.2.2. By Age Group
        • 12.8.1.2.3. By Distribution Channel
    • 12.8.2. Canada Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Drug
        • 12.8.2.2.2. By Age Group
        • 12.8.2.2.3. By Distribution Channel

13. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Drug
    • 13.3.3. By Age Group
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug
    • 13.4.3. By Age Group
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug
        • 13.8.1.2.2. By Age Group
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug
        • 13.8.2.2.2. By Age Group
        • 13.8.2.2.3. By Distribution Channel
    • 13.8.3. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Drug
        • 13.8.3.2.2. By Age Group
        • 13.8.3.2.3. By Distribution Channel

14. Europe Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Drug
    • 14.3.3. By Age Group
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug
    • 14.4.3. By Age Group
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug
        • 14.8.1.2.2. By Age Group
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Italy Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug
        • 14.8.2.2.2. By Age Group
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. France Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug
        • 14.8.3.2.2. By Age Group
        • 14.8.3.2.3. By Distribution Channel
    • 14.8.4. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.4.2.1. By Drug
        • 14.8.4.2.2. By Age Group
        • 14.8.4.2.3. By Distribution Channel
    • 14.8.5. Spain Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.5.2.1. By Drug
        • 14.8.5.2.2. By Age Group
        • 14.8.5.2.3. By Distribution Channel
    • 14.8.6. BENELUX Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.6.2.1. By Drug
        • 14.8.6.2.2. By Age Group
        • 14.8.6.2.3. By Distribution Channel
    • 14.8.7. Russia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.7.2.1. By Drug
        • 14.8.7.2.2. By Age Group
        • 14.8.7.2.3. By Distribution Channel

15. East Asia Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Drug
    • 15.3.3. By Age Group
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug
    • 15.4.3. By Age Group
    • 15.4.4. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug
        • 15.8.1.2.2. By Age Group
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. Japan Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug
        • 15.8.2.2.2. By Age Group
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug
        • 15.8.3.2.2. By Age Group
        • 15.8.3.2.3. By Distribution Channel

16. South Asia Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Drug
    • 16.3.3. By Age Group
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug
    • 16.4.3. By Age Group
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug
        • 16.8.1.2.2. By Age Group
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug
        • 16.8.2.2.2. By Age Group
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Malaysia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug
        • 16.8.3.2.2. By Age Group
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Thailand Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Drug
        • 16.8.4.2.2. By Age Group
        • 16.8.4.2.3. By Distribution Channel

17. Oceania Attention Deficit Hyperactivity Disorder Therapeutics Market 2019-2024 and Forecast 2025-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Drug
    • 17.3.3. By Age Group
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug
    • 17.4.3. By Age Group
    • 17.4.4. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Australia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug
        • 17.8.1.2.2. By Age Group
        • 17.8.1.2.3. By Distribution Channel
    • 17.8.2. New Zealand Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug
        • 17.8.2.2.2. By Age Group
        • 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
  • 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. North Africa
      • 18.3.1.4. South Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Drug
    • 18.3.3. By Age Group
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug
    • 18.4.3. By Age Group
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Drivers and Restraints - Impact Analysis
  • 18.7. Key Players - Intensity Mapping
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. GCC Countries Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug
        • 18.8.1.2.2. By Age Group
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug
        • 18.8.2.2.2. By Age Group
        • 18.8.2.2.3. By Distribution Channel
    • 18.8.3. South Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.3.2.1. By Drug
        • 18.8.3.2.2. By Age Group
        • 18.8.3.2.3. By Distribution Channel
    • 18.8.4. North Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.4.2.1. By Drug
        • 18.8.4.2.2. By Age Group
        • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Benchmarking
  • 20.3. Competition Deep Dive
    • 20.3.1. Pfizer Inc.
      • 20.3.1.1. Overview
      • 20.3.1.2. Product Portfolio
      • 20.3.1.3. Sales Footprint
      • 20.3.1.4. Key Financials
      • 20.3.1.5. SWOT Analysis
      • 20.3.1.6. Strategy Overview
    • 20.3.2. Eli Lilly and Company
      • 20.3.2.1. Overview
      • 20.3.2.2. Product Portfolio
      • 20.3.2.3. Sales Footprint
      • 20.3.2.4. Key Financials
      • 20.3.2.5. SWOT Analysis
      • 20.3.2.6. Strategy Overview
    • 20.3.3. Novartis AG
      • 20.3.3.1. Overview
      • 20.3.3.2. Product Portfolio
      • 20.3.3.3. Sales Footprint
      • 20.3.3.4. Key Financials
      • 20.3.3.5. SWOT Analysis
      • 20.3.3.6. Strategy Overview
    • 20.3.4. GlaxoSmithKline PLC
      • 20.3.4.1. Overview
      • 20.3.4.2. Product Portfolio
      • 20.3.4.3. Sales Footprint
      • 20.3.4.4. Key Financials
      • 20.3.4.5. SWOT Analysis
      • 20.3.4.6. Strategy Overview
    • 20.3.5. Mallinckrodt Pharmaceuticals
      • 20.3.5.1. Overview
      • 20.3.5.2. Product Portfolio
      • 20.3.5.3. Sales Footprint
      • 20.3.5.4. Key Financials
      • 20.3.5.5. SWOT Analysis
      • 20.3.5.6. Strategy Overview
    • 20.3.6. Hisamitsu Pharmaceutical Co., Inc.
      • 20.3.6.1. Overview
      • 20.3.6.2. Product Portfolio
      • 20.3.6.3. Sales Footprint
      • 20.3.6.4. Key Financials
      • 20.3.6.5. SWOT Analysis
      • 20.3.6.6. Strategy Overview
    • 20.3.7. Johnson & Johnson
      • 20.3.7.1. Overview
      • 20.3.7.2. Product Portfolio
      • 20.3.7.3. Sales Footprint
      • 20.3.7.4. Key Financials
      • 20.3.7.5. SWOT Analysis
      • 20.3.7.6. Strategy Overview
    • 20.3.8. UCB S.A.
      • 20.3.8.1. Overview
      • 20.3.8.2. Product Portfolio
      • 20.3.8.3. Sales Footprint
      • 20.3.8.4. Key Financials
      • 20.3.8.5. SWOT Analysis
      • 20.3.8.6. Strategy Overview
    • 20.3.9. Purdue Pharma L.P.
      • 20.3.9.1. Overview
      • 20.3.9.2. Product Portfolio
      • 20.3.9.3. Sales Footprint
      • 20.3.9.4. Key Financials
      • 20.3.9.5. SWOT Analysis
      • 20.3.9.6. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology